ArticleCellular oncology (Dordrecht, Netherlands)2026
Role of DDX39A in modulating the tumor progression and radiosensitivity in esophageal squamous cell carcinoma.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeEsophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with limited treatment options. Although radiotherapy remains a cornerstone of curative treatment, intrinsic and acquired radioresistance frequently lead to locoregional recurrence and disease progression. DDX39A, a DEAD-box RNA helicase, regulates RNA metabolism in diverse cellular contexts; however, its role in ESCC pathogenesis and therapeutic resistance remains unclear.
methodsBioinformatics analyses, immunohistochemistry, and functional assays were performed to characterize the role of DDX39A in ESCC. Tandem mass tag-based proteomics was used to identify downstream effectors. Mechanistic studies included RIP-qPCR, ChIP-qPCR, and dual-luciferase reporter assays. The therapeutic relevance was further validated using murine xenograft models.
resultsDDX39A was significantly upregulated in ESCC tissues and cell lines, and its high expression correlating with increased tumor proliferation. DDX39A knockdown suppressed malignant phenotypes and markedly enhanced radiosensitivity. Mechanistically, SP1 was prioritized from proteomic screening owing to its central role as a transcription factor regulating DNA repair gene expression. DDX39A directly binds to SP1 mRNA, stabilizing it and enhancing its translation efficiency without affecting transcription. The resulting increase in SP1 protein promotes binding to the − 223/−214 bp region of the Ku70 promoter, thereby transcriptionally activating this key component of the non-homologous end joining pathway and contributing to radioresistance. Rescue experiments confirmed that the DDX39A–SP1–Ku70 axis is both necessary and sufficient to mediate radioresistance. In vivo, DDX39A silencing enhanced radiosensitivity and improved tumor control in ESCC models.
conclusionsThese findings identify DDX39A as a promising therapeutic target in ESCC radioresistance. The DDX39A–SP1–Ku70 axis provides a mechanistic rationale for the development of novel radiosensitization strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.